Photo by Wirestock
On Friday, July 25, 2025, the New York Cannabis Control Board (CCB) convened its monthly meeting at the Hudson Valley Community College in Troy, New York. The public session, broadcast online, included licensing decisions, regulatory proposals, research updates, and public commentary.
Retroactive Licensing Surge
This month, the board approved 52 adult‑use cannabis licenses, pushing the statewide total to 1,851 licenses issued to date. Notably, approximately 62% of these new licenses are held by Social and Economic Equity (SEE) licensees, reaffirming New York’s commitment to equity-driven market inclusion.
These licenses cover a spectrum of categories including retail dispensaries, microbusinesses, processors, distributors, and cultivators, further diversifying the state’s cannabis infrastructure. Patrick McKeage, executive deputy director at the Office of Cannabis Management (OCM), provided a detailed breakdown of application processing progress from both the November and December 2023 queues. Of the 1,603 applications in the November queue, 674 have been granted final licenses. Another 239 have provisional approval pending location confirmation, while 321 remain under active review, and 369 have been closed due to denial, withdrawal, or void status. The December queue remains paused until the November applications are fully processed, with over 4,600 applications pending—including 2,704 for retail dispensaries and 872 for microbusinesses.
McKeage acknowledged the challenge of delays, noting that many applicants are now being contacted over a year after initial submission. But he emphasized that officials anticipate a new licensing cohort in September.
Amendments to Licenses: Locations and Cultivation Adjustments
The board also addressed requested amendments to existing licenses—specifically location changes and changes in cultivation tier (e.g., canopy size). These adjustments aim to enhance licensee flexibility and operational viability across both urban and rural settings.
Research Oversight: Annual Report Reviewed
The board formally accepted the annual report on its cannabis research license program. The report highlights development progress on research initiatives including potency standards, a genetic study, and cultivation best practices. This underscores ongoing oversight of science-based policy expansion.
Registered Organization Expansion
In a separate resolution, the board approved facility requests from existing Registered Organizations to expand their dispensing and manufacturing operations. These amendments support better capacity utilization and geographic reach for licensed medical cannabis entities.
Packaging, Labeling and Marketing: Draft Regulations Enter Public Comment
The CCB initiated public review of proposed updates to packaging, labeling, marketing, and advertising regulations. The draft removes or softens restrictions prohibiting discount promotions, price advertising, loyalty programs, and outdoor signage—provided public health protections remain in place. This proposal represents a shift toward enabling legal operators to better compete with illicit cannabis vendors.
Policy Revisions: Addressing Closed Applications and Delegated Authority
The board passed another resolution concerning applications it closed under the Supplemental Policy Guidance first issued in May 2024. At the time, this guidance prevented prospective dispensary owners from applying for more than one retail license. After a court ruled that policy invalid, the board directed the OCM to reach out to affected applicants to offer reinstatement. This was contingent on meeting licensing criteria. The policy change affected nearly 400 applicants who should monitor their email inbox for communication.
The CCB also approved a move to delegate certain denial powers from the board directly to OCM. The intention is to streamline future applicant review and adjudication under standard criteria.
Administrative Appeal Rendered
The board issued a ruling relating to Brecken Gold Athletics NYC LLC (dba Breckenridge Hemp Co.), concluding an inspection and compliance matter. This highlights ongoing regulatory enforcement and the robust appeal process under the Cannabis Law.
Market Context: Sales Near $2 Billion
In a press release issued the same day, OCM noted that New York’s retail cannabis sales are approaching $2 billion since market launch. They emphasized the November-queue application process remains critical to continued license rollouts. They also reminded licensees to comply with PowerScore deadline regulations. The regulations aim to ensure timely progress in application reviews. The PowerScore system evaluates whether applicants who have received provisional approval—typically pending final location and compliance documentation—are actively advancing toward full licensure.
Applicants who fail to meet critical benchmarks by the deadlines may risk having their applications deprioritized or even denied. By reviewing PowerScore outcomes, OCM aims to ensure that only committed and prepared operators continue through the licensing process. This thereby frees up capacity to process new applications and accelerate the market’s expansion.
This approach reflects OCM’s broader effort to maintain momentum while increasing accountability and transparency within the licensing pipeline. The board highlighted continued expansion of social and economic equity participants, signaling that more than half of new licenses support historically disadvantaged applicants.
Challenges and Equity: The Broader Picture
While the board made significant strides in licensing and regulatory reform, challenges persist—especially for equity applicants waiting for clarity on reinstated applications and grant eligibility. Many raised concerns over compliance timelines, bureaucratic delays, and evolving enforcement standards.
The launch of new Packaging, Labeling, Marketing, and Advertising (PLMA) regulations signals an intent to reduce business friction. But equity licensees have called for further support, especially on logistics like refrigeration storage, multi-serve edible production, and laboratory compliance costs.
As Acting Executive Director Felicia A.B. Reid noted: equity and small business success remain central to New York’s cannabis strategy.
Regulatory Momentum with Equity at the Forefront
The July CCB meeting delivered substantial progress: over 50 new licenses—with strong social equity representation, research advancement, and regulatory flexibility on the table. Decisions to reinstate eligible applicants and delegate administrative authority are steps toward a more efficient licensing landscape.
With near‑$2 billion in retail sales and equity licensees front and center, New York continues evolving as a leading model for inclusive and regulated cannabis markets. The coming public comment cycle on PLMA rules and the next board session in September will further define the trajectory.
Leave a Reply